Kardiorespirator tadqiqotlar jurnali 4, 2021-yil

Maqola mavzusi

ORTIQCHA VAZN ARTERIAL GIPERTENZIYA PAYDO BO`LISHIGA OLIB KELUVCHI SABABLARDAN BIRI (18-21)

Mualliflar

Nasirova Z.A., Safarov J.A., Xalilov N.X.

Muassasa

Samarqand davlat tibbiyot instituti

Annotatsiya

Hozirgi vaqtda dunyoning aksariyat mamlakatlarida metabolik xavf omillariga katta ahamiyat berilmoqda, chunki metabolik sindrom (MS) rivojlanishining kuchayishi tendensiyasi mavjud. Arterial gipertenziya (AG) metabolik kasalliklar bilan og'rigan bemorlar orasida eng ko`p tarqalgan xavf omili bo'lib, yurak-qon tomir kasalliklari asoratlari xavfini oshiradi. Qorin bo'shlig'idagi semirish, arterial gipertenziya (AG), dislipidemiya va insulin qarshiligi kabi quyidagi xavf omillarini birlashtirgan metabolik sindrom yurak-qon tomir kasalliklari va falokatlarning bashoratchisi hisoblanadi. Simptomlar majmuasining 17 ta yurak-qon tomir kasalliklarini (YQTK) rivojlanish ehtimolini oshiradigan mexanizmlar faqat qisman tushuniladi. Buning sabablaridan biri elastiklikning yo'qolishi va endotelial disfunktsiyaning (ED) rivojlanishi bilan namoyon bo'ladigan katta tomirlardagi erta o'zgarishlar bo'lishi mumkin. Shunday qilib, metabolik sindrom (MS) yurak-qon tomir kasalliklarining rivojlanishi uchun eng muhim xavf omillarining kombinatsiyasi hisoblanadi: buzilgan uglevod almashinuvi, semizlik, dislipidemiya va arterial gipertenziya (AG). Metabolik sindromning haqiqiy sindrom majmuasimi yoki alohida-alohida emas, balki birgalikda ko'proq uchraydigan xavf omillarining kombinatsiyasi ekanligi haqida hali ham kelishmovchiliklar mavjud.

Kalit so'zlar

endotelial disfunktsiya, metabolik sindrom, dislipidemiya, yurak-qon tomir kasalliklari, qo'shma kasalliklar.

Adabiyotlar

1. Nasirova Z.A., Tashkenbayeva E.N., Nasirova D.A. Psixosomatik holatlarning yurak qon tomir kasalliklari bilan aloqasi //cardio. – 2020. – Т. 1. – №. 3. 2. Nasirova Z.A., Tashkenbayeva E.N. Yurak ishemik kasalliklarig depressiv sindrom va yalig`langan sitokenli genlarnin ta’siri //axborotnomasi. – С. 53. 3. Tashkenbayeva E.N., Nasirova Z.A., Mirzayev R.Z. Surunkali ishemik yurak kasalligining diagnostika usullari va ularni davolash usullariga qarab tabaqalanishi//Kardiorespirator tadqiqotlar jurnali – 2020. – Т. 1. – №. 3. 4. Ellamonov S.N. va boshqalar. 2-tip qandli diabet bilan kasallangan bemorlarda arterial gipertenziya kasalligining rivojlanishining omillari// Kardiorespirator tadqiqotlar jurnali. – 2021. – Т. 2. – №. 2. 5. Oelze M., Glutathione peroxidase-1 deficiency potentiates disregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. / M. Oelze, S. Kroller-Schon, S. Steven et al. // Hypertension. ― 2014 ― Vol. 63 ― P.390-396 6. O. Brien, E. Unmasking hypertension/ E. O,Brien // Hypertension. ― 2005. ― Vol. 45, № 4. ― P. 481-482. 218. O ,Rourke, M.F Guidelines on guidelines: focus on isolated systolic hypertension in youth / M.F. O,Rourke, A. Adji // J. Hypertens. ― 2013. ― Vol. 31. ― Р. 649- 654. 7. Palatini, P. Arterial stiffnes, central hemodynamics, and cardiovascular risk in hypertension / P. Palatini, E. Casiglia, G. Gasowski // Vasc. Health Risk Manag. ― 2011. ― №7. ― Р. 725-39. 8. Piepoli, M.F. European Guidelines on cardiovascular disease prevention in clinical practice / M.F. Piepoli, A.W. Hoes, S. Agewall, C. Albus, C. Brotons, A.L. Catapano, M.T. Cooney, U. Corrà, B. Cosyns, C. Deaton, I. Graham, M.S. Hall, F.D.R. Hobbs, M.L. Løchen, H. Löllgen, P. Marques-Vidal, J. Perk, E. Prescott, J. Redon, D.J. Richter, N. Sattar, Y. Smulders, M. Tiberi, H.B. van der Worp, I. van Dis, W.M.M.G. Verschuren // European Heart Journal. ― 2016. ― № 37. ― P. 2315-2381. 9. Ragot S. Prevalence and management of hypertensive patients in clinical practice: Cross-sectional registry in five countries outside the European Union Blood Press. / S. Ragot, M. Beneteau, F. Guillou-Bonnici et al. // Taylor & Francis. ― 2016. ― Vol. 25, № 2. ― P. 104- 116. 10. Terawaki, H. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study / H. Terawaki, M. Nakayama, E. Miyazawa, et al. // Clinical and Exp Nephrol. ― 2013. ― № 17(4). ― P. 549-53. 11. Tessari, P. Roles of insulin, age, and assimetric dimethylarginine, on nitric oxide synthesis in vivo / P. Tessari, D. Cecchet, C. Artusi et al. // Diabetes. ― 2013. ― № 62 (10). ― P. 2699-2708.12. Tocci, G. Trends in blood pressure levels and control in Italy: Comparative analysis of clinical data from 2000-2005 and 2006-2011 hypertension surveys / G. Tocci, A. Ferrucci, R. Pontremoli et al. // High Blood Press. Cardiovasc. Prev. Nature Publishing Group. ― 2014. ― Vol. 21 (4). ― P. 300-301. 13. Tosello, F. Ascending aortic dilatation, arterial stiffness and cardiac organ damage in essential hypertension / F. Tosello, A. Milan, G. Bruno et al. // Artery Research. — 2012. — V. 6. — № 4. — P. 162. 14. Tsioufis, C. Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk/ C. Tsioufis, P. Kokkinos, C. Macmanus, C. Thomopoulos, C. Faselis, M. Doumas, C. Stefanadis, V. Papademetriou // J. Hypertens. ― 2010. ― № 28. ― P. 2299-2308. 15. Soltani, Z. Potential Role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and Cardiovascular Diseases: Is It Time for Reappraisal? / Z. Soltani, R. Rasheed, D.R. Kapusta, E. Reisin // Curr Hypertens Rep. ― 2013. ― №15 (3). P. 175-81. 234. Scientific Organizing Committee of the RF-ESSAY. Epidemiology of cardiovascular disease in different regions of Russia (ESSAY-RF). Rationale and study design. // Preventive Medicine. ― 2013. № 6. P. 25-34. 16. Sundstrom, J. Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts / J. Sundstrom, M. Neovius, P. Tynelius, F. Rasmussen // BMJ. ― 2011. 342. P. d643. 17. Van Bortel, L. M. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid ― femoral pulse wave velocity / L. M. Van Bortel, S. Laurent, P. Boutouyrie et al. // J Hypertens. ― 2012. ― № 30(3). ― P. 445-8